Back to top
more

Sangamo Therapeutics (SGMO)

(Real Time Quote from BATS)

$0.25 USD

0.25
5,523,525

0.00 (-1.85%)

Updated Apr 9, 2026 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 8% in Session

by Zacks Equity Research

Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

    Zacks Equity Research

    Gilead's CAR-T Therapy Yescarta Gets Approval in Europe

    by Zacks Equity Research

    Gilead's (GILD) CAR-T therapy, Yescarta gets approval in Europe for adult patients suffering from relapsed or refractory DLBCL and PMBCL, after two or more lines of systemic therapy.

      Zacks Equity Research

      Is the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.

        Zacks Equity Research

        Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

        by Zacks Equity Research

        Sangamo (SGMO) delivered earnings and revenue surprises of -13.33% and -31.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          Madeleine Johnson headshot

          Bull of the Day: Illumina (ILMN)

          by Madeleine Johnson

          Invest in the medical space with this DNA sequencing-focused company.

            Zacks Equity Research

            Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit

            by Zacks Equity Research

            Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.

              Zacks Equity Research

              Options Traders Expect Huge Moves in Sangamo Therapeutics (SGMO) Stock

              by Zacks Equity Research

              Sangamo Therapeutics (SGMO) needs investors to pay close attention to the stock based on moves in the options market lately.

                Kevin Cook headshot

                CRISPR Science and Stocks: Knowing Enough to Invest

                by Kevin Cook

                Can you learn enough about the science and the companies to invest with confidence?

                  Zacks Equity Research

                  Gilead Collaborates with Hookipa for HBV and HIV Therapies

                  by Zacks Equity Research

                  Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.

                    Zacks Equity Research

                    Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV

                    by Zacks Equity Research

                    Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.